Cargando…
Galectin-3 Impairment of MYCN-Dependent Apoptosis-Sensitive Phenotype Is Antagonized by Nutlin-3 in Neuroblastoma Cells
MYCN amplification occurs in about 20–25% of human neuroblastomas and characterizes the majority of the high-risk cases, which display less than 50% prolonged survival rate despite intense multimodal treatment. Somehow paradoxically, MYCN also sensitizes neuroblastoma cells to apoptosis, understandi...
Autores principales: | Veschi, Veronica, Petroni, Marialaura, Cardinali, Beatrice, Dominici, Carlo, Screpanti, Isabella, Frati, Luigi, Bartolazzi, Armando, Gulino, Alberto, Giannini, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494673/ https://www.ncbi.nlm.nih.gov/pubmed/23152863 http://dx.doi.org/10.1371/journal.pone.0049139 |
Ejemplares similares
-
Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma
por: Petroni, Marialaura, et al.
Publicado: (2012) -
Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors
por: Veschi, V, et al.
Publicado: (2014) -
MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011) -
A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors
por: Di Giulio, Stefano, et al.
Publicado: (2021) -
MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors
por: Petroni, Marialaura, et al.
Publicado: (2018)